haemophilia B
First UK patient treated with CSL Behring’s gene therapy for Haemophilia B
June 20, 2025Research and Development CSL Behring, Haematology, NHS England, cell therapy, gene therapy, haemophilia B, prophylactic infusions
CSL Behring has announced that the first patient in the UK has received HEMGENIX (etranacogene dezaparvovec) through the NHS, marking …
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
May 22, 2025Market Access, Research and Development Haematology, Hympavzi, NHS, NICE, Pfizer, haemophilia B, marstacimab
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care Excellence (NICE) has published final …
NHS Scotland gives green light to funding haemophilia A drug Hemlibra
December 18, 2019Research and Development NHS, haemophilia, haemophilia B, haemophilia a, nhs scotland
NHS Scotland has commissioned Hemlibra (emicizumab), by Chungai Pharma UK Ltd and Roche Products Ltd, to treat people with congenital …
Irish haemophilia A patients to get continued access to Sobi’s extended half-life factor replacement therapy
December 17, 2019Manufacturing and Production haemophilia, haemophilia B, haemophilia a
The Republic of Ireland’s Haemophilia Product Selection and Monitoring Advisory Board (HPSMAB) and Sobi United Kingdom and Republic of Ireland, …
Pfizer and Spark Therapeutics granted FDA breakthrough designation for haemophilia drug
July 22, 2016Medical Communications, Research and Development FDA, Pfizer, Spark Therapeutics, haemophilia B, spk-9001
Pfizer and Spark Therapeutics have announced that the US Food and Drug Administration (FDA) has granted a breakthrough therapy designation …
Pfizer and Spark Therapeutics present early data on bio-engineered haemophilia drug
May 23, 2016Research and Development, Sales and Marketing Pfizer, Spark Therapeutics, gene therapy, haemophilia B
Pfizer (NYSE: PFE) and Spark Therapeutics (NASDAQ: ONCE) have announced that they will present data showing encouraging signs in their …
EU approves Idelvion for haemophilia B treatment
May 13, 2016Medical Communications, Research and Development CSL, EU, Idelvion, approval, haemophilia B
The European Commission has approved Idelvion, coagulation Factor IX (recombinant) for the treatment and prophylaxis of bleeding in patients with …
Sobi, Biogen’s haemophilia B therapy gets European approval
May 13, 2016Medical Communications, Research and Development, Sales and Marketing Biogen, haemophilia B, orphan designation, regulation, sobi
Sobi (STO: SOBI) and Biogen (Nasdaq: BIIB) on Friday said the European Commission has approved their drug to treat haemophilia B. The …
Albumedix technology extends dosing interval in Behring haemophilia B drug
March 22, 2016Manufacturing and Production, Research and Development Albumedix, GSK, Idelvion, Novozymes, VELTIS, haemophilia B
Novozymes subsidiary Albumedix has scored another big pharma tie-up for its albumin-based half-life extension technology VELTIS, which this time is …
Late-stage Pfizer drug study shows significant reduction in haemophilia B bleeding
March 9, 2016Research and Development BeneFIX, Pfizer, haemophilia B
Pfizer on Wednesday said late-stage trials for its drug candidate to treat haemophilia B showed prophylactic use resulted in significant reduction …
